Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Prime Medicine's PM-359?
PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease....